S'abonner

Regional changes in stimulant drug use during COVID-19 pandemic in Finland: A wastewater study - 15/08/22

Doi : 10.1016/j.toxac.2022.06.204 
Aino Kankaanpää , Teemu Gunnar
 Forensic chemistry unit, Finnish institute for health and welfare (thl), Helsinki, Finland 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Aim

Since March of 2020, tight measures against COVID-19, newly declared as pandemic by World Health Organization, affected almost all areas of our lives. Similarly, as with other aspects of community life, marked changes were expected to take place in the drug scene during and after the first lockdown period (16.3.2020–14.4.2020 in Finland). Wastewater-based epidemiology (WBE) is an approach established as an objective means for monitoring regional drug use. In Finland, we began WBE in 2012 with ten cities, and ended up to 27 cities (approximately 60% of Finnish population) since 2020. This study illustrates regional trends in stimulant drug use in Finland during the COVID-19 pandemic as a part of trend monitoring for up to 10 years.

Method

Composite 24-h samples of untreated wastewater were collected twice a year during one-week sampling periods from the inlets of wastewater treatment plants. Every other year 1-2 sampling campaigns were performed in the four biggest cities only. In 2020, two extra sampling periods (total of four periods) were carried out to evaluate the impact of measures against COVID-19 on drug use. Samples were analyzed with a fully validated UHPLC-MS/MS system. Daily drug consumption was calculated from the measured concentrations of the drugs or their metabolites in wastewater.

Results

While the stimulant drug consumption has been steadily increasing in Finland during the years of WBE, in 2020 the overall trend leveled off, with drug use being in higher level than ever before. However, the changes observed after the first quarter of 2020 varied markedly in different cities, with deepest decrease in Mariehamn, Åland, and highest increases in Lappeenranta and Vihti. During 2021, consumption of amphetamine, the dominant stimulant drug in Finland, was reduced by half from March to November/December. Instead, cocaine use remained in its newly increased level in Helsinki metropolitan area, bringing consumption of these two drugs record close to each other.

COVID-19 measures may have played a role in the leveling observed in overall stimulant drug use trend, but the changes varied regionally and remained minor and transient in most cities. It seems that drug use was less affected by lockdown in 2020, as well as other measures, than many other societal phenomena. The marked fall of amphetamine consumption observed after spring of 2021 is temporally related to large seizures of drugs, which may have exhausted drug supplies. However, it can be speculated whether COVID-19 measures may have, for their part, delayed the recovery of illicit market after the seizures. Although the overall national drug situation is by far dominated by the biggest cities with largest populations, this study with opposing drug use trends in different cities shows again the importance of including a range of cities with different sizes and geographical locations in monitoring programs, both for a realistic picture of the overall drug situation, and to be able to offer objective and comparable data to various actors of both national and local level.

Conclusion

Drug use was less affected by measures against COVID-19 than many other societal phenomena. To obtain a realistic picture of the multifaceted drug situation, both during normal and exceptional circumstances such as COVID-19, it is essential to include a representative and wide enough selection of cities in monitoring programs.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 34 - N° 3S

P. S125 - septembre 2022 Retour au numéro
Article précédent Article précédent
  • Nicotine poisoning-related deaths in Seoul Capital Area, Korea, 2014–2021
  • Minji Kang, Sungmin Moon, Byungjoo Kim, So-Hyun Kim, Junghyun Kim, Hyeyoung Choi, Sanggil Choe
| Article suivant Article suivant
  • Development and application of a real-time Integrated Drugs Surveillance System (iDSS) for NPS in New Zealand
  • Diana Kappatos, Cameron Johnson, Wendy Popplewell, Dawen Li, Sarah Russell, Mary-Jane Mccarthy

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.